Brief: Royalty Pharma Reports Q4 And Full Year 2023 Results
15/02/2024 13:43
Feb 15 (Reuters) - Royalty Pharma PLC RPRX.O :
* ROYALTY PHARMA REPORTS Q4 AND FULL YEAR 2023 RESULTS
* EXPECTS 2024 PORTFOLIO RECEIPTS TO BE BETWEEN $2,600
MILLION AND
$2,700 MILLION.
* 2024 PORTFOLIO RECEIPTS GUIDANCE INCLUDES EXPECTED GROWTH
IN
ROYALTY RECEIPTS OF 5% TO 9%.
Source text for Eikon: ID:nGNX4bsbWf
Further company coverage: RPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)